[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer

Introduction Theranostics targeting prostate-specific membrane antigen (PSMA) represent a new targeted approach for prostate cancer care that combines diagnostic and therapeutic radiopharmaceuticals to diagnose and treat the disease. Positron emission tomography (PET) is the imaging method of choice and several diagnostic radiopharmaceuticals for quantifying PSMA have received FDA approval and are in clinical use. [Ga-68]Ga-PSMA-11 is one such imaging agent and the focus of this article. One beta-emitting radioligand therapy ([Lu-177]Lu-PSMA-617) has also received FDA approval for prostate cancer treatment, and several other alpha- and beta-emitting radioligand therapies are in clinical trials. Areas covered Theranostics targeting PSMA in men with prostate cancer are discussed with a focus on use of [Ga-68]Ga-PSMA-11 for imaging PSMA-positive lesions in men with prostate cancer. The review covers [Ga-68]Ga-PSMA-11 manufacture, current regulatory status, comparison of [Ga-68]Ga-PSMA-11 to other imaging techniques, clinical updates, and emerging applications of artificial intelligence for [Ga-68]Ga-PSMA-11 PET. Expert opinion [Ga-68]Ga-PSMA-11 is used in conjunction with a PET/CT scan to image PSMA positive lesions in men with prostate cancer. It is manufactured by chelating precursor with(68)Ga, either from a generator or cyclotron, and has regulatory approval around the world. It is widely used clinically in conjunction with radioligand therapies like [Lu-177]Lu-PSMA-617.